Rocket Pharmaceuticals (RCKT) Receives a Buy from Bank of America Securities

Tip Ranks
2025.11.18 11:38
portai
I'm PortAI, I can summarize articles.

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Rocket Pharmaceuticals with a price target of $8.00. Zemansky has an average return of 21.3% and a 60.64% success rate. Wedbush’s Yun Zhong also rated Rocket Pharmaceuticals a Buy, while Needham maintained a Hold rating.

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Rocket Pharmaceuticals today and set a price target of $8.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Zemansky covers the Healthcare sector, focusing on stocks such as Cytokinetics, Kura Oncology, and Arcus Biosciences. According to TipRanks, Zemansky has an average return of 21.3% and a 60.64% success rate on recommended stocks.

In addition to Bank of America Securities, Rocket Pharmaceuticals also received a Buy from Wedbush’s Yun Zhong in a report issued on November 7. However, on the same day, Needham maintained a Hold rating on Rocket Pharmaceuticals (NASDAQ: RCKT).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer